These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
62. Clinical use of antacids. Halter F J Physiol Pharmacol; 1993 Sep; 44(3 Suppl 1):61-74. PubMed ID: 8260736 [TBL] [Abstract][Full Text] [Related]
63. When should stress ulcer prophylaxis be used in the ICU? Quenot JP; Thiery N; Barbar S Curr Opin Crit Care; 2009 Apr; 15(2):139-43. PubMed ID: 19578324 [TBL] [Abstract][Full Text] [Related]
64. [Etiopathogenesis of peptic ulcer in the light of current viewpoints]. Banach S; Kuczyńska-Sekieta K Pieleg Polozna; 1982; (10):16-7. PubMed ID: 6925835 [No Abstract] [Full Text] [Related]
65. [Anti-ulcer effectiveness of mono- and dibasic carbamates with local anesthetic effects]. Gombosová I; Valentová J; Svec P Cesk Farm; 1993 Dec; 42(6):283-6. PubMed ID: 8111862 [TBL] [Abstract][Full Text] [Related]
66. A randomized, pharmacokinetic and pharmacodynamic, cross-over study of duodenal or jejunal administration compared to nasogastric administration of omeprazole suspension in patients at risk for stress ulcers. Phillips JO; Olsen KM; Rebuck JA; Rangnekar NJ; Miedema BW; Metzler MH Am J Gastroenterol; 2001 Feb; 96(2):367-72. PubMed ID: 11232677 [TBL] [Abstract][Full Text] [Related]
67. Study of outcome after targeted intervention for peptic ulcer resistant to acid suppression therapy. Lanas A; Remacha B; Sáinz R; Hirschowitz BI Am J Gastroenterol; 2000 Feb; 95(2):513-9. PubMed ID: 10685760 [TBL] [Abstract][Full Text] [Related]
69. Role of protective drugs in the prevention of ulcer relapse. Ota S; Terano A J Gastroenterol; 1994 Jul; 29 Suppl 7():139-40. PubMed ID: 7921147 [TBL] [Abstract][Full Text] [Related]
70. Prevention and treatment of non-steroidal anti-inflammatory drug-induced gastro-duodenal damage: rationale for the use of antisecretory compounds. Scarpignato C; Pelosini I Ital J Gastroenterol Hepatol; 1999; 31 Suppl 1():S63-72. PubMed ID: 10379472 [TBL] [Abstract][Full Text] [Related]
71. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. Lai KC; Chu KM; Hui WM; Wong BC; Hu WH; Wong WM; Chan AO; Wong J; Lam SK Am J Med; 2005 Nov; 118(11):1271-8. PubMed ID: 16271912 [TBL] [Abstract][Full Text] [Related]
72. Stress-related mucosal disease. Pathophysiology, prevention, and treatment. Fisher RL; Pipkin GA; Wood JR Crit Care Clin; 1995 Apr; 11(2):323-45. PubMed ID: 7788535 [TBL] [Abstract][Full Text] [Related]
73. Stress, cigarettes, and ulcers. Cummings S Gastroenterology; 1983 Nov; 85(5):1232. PubMed ID: 6618113 [No Abstract] [Full Text] [Related]
74. [Prevention of stress ulcer in intensive care medicine--state of the art. A symposium, Mainz, 26 September 1989]. Z Gastroenterol; 1991 Jan; 29 Suppl 1():1-51. PubMed ID: 1683730 [No Abstract] [Full Text] [Related]
75. The prevention of acute gastric ulcer in the rat by alpha-methyldopa. Djahanguiri B; Hemmati S; Sadeghi D; Firouzabadi A Med Pharmacol Exp Int J Exp Med; 1967; 17(5):427-33. PubMed ID: 5632205 [No Abstract] [Full Text] [Related]
76. [Comparative effects of atropine and N-octylatropinium on stress ulcers in albino rats and mice]. Mercier J; Lumbroso S Therapie; 1966; 21(6):1537-42. PubMed ID: 6002950 [No Abstract] [Full Text] [Related]
77. [On the course of peptic ulcer in young persons and its prevention]. Konstantinovskiĭ AF Voen Med Zh; 1965 Dec; 12():25-9. PubMed ID: 5874680 [No Abstract] [Full Text] [Related]